209 related articles for article (PubMed ID: 11820155)
1. [Hyperlipidemia and fibrates with special reference to diabetes].
Henkel E; Hanefeld M
Herz; 2001 Dec; 26(8):523-30. PubMed ID: 11820155
[TBL] [Abstract][Full Text] [Related]
2. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Nesto RW
Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
[TBL] [Abstract][Full Text] [Related]
3. [Lipid therapy in patients with diabetes].
Saely CH; Drexel H
Wien Med Wochenschr; 2010 Jan; 160(1-2):25-9. PubMed ID: 20229158
[TBL] [Abstract][Full Text] [Related]
4. [Statins in diabetic hyperlipidemia].
Kirchmair R; Sturm W; Gänzer H; Patsch JR
Wien Med Wochenschr; 1999; 149(5-6):139-43. PubMed ID: 10408005
[TBL] [Abstract][Full Text] [Related]
5. Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives.
Chapman MJ
Atherosclerosis; 2003 Nov; 171(1):1-13. PubMed ID: 14642400
[TBL] [Abstract][Full Text] [Related]
6. Managing diabetic dyslipidemia: beyond statin therapy.
Neeli H; Gadi R; Rader DJ
Curr Diab Rep; 2009 Feb; 9(1):11-7. PubMed ID: 19192419
[TBL] [Abstract][Full Text] [Related]
7. [Update: clinical lipidology].
Parhofer KG
MMW Fortschr Med; 2013 Jul; 155(13):49-52; quiz 53-4. PubMed ID: 23964509
[No Abstract] [Full Text] [Related]
8. [Statins and diabetic hyperlipidemia].
Vergès B
Ann Endocrinol (Paris); 2001 Feb; 62(1 Pt 2):128-32. PubMed ID: 11240415
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].
Kłosiewicz-Latoszek L; Respondek W; Białobrzeska-Paluszkiewicz J; Grzybowska B; Jakóbisiak-Ostasz B; Stolarska I
Pol Merkur Lekarski; 2003 Jul; 15(85):42-6. PubMed ID: 14593958
[TBL] [Abstract][Full Text] [Related]
10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
Cziraky MJ; Watson KE; Talbert RL
J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Cottrell DA; Marshall BJ; Falko JM
Curr Opin Cardiol; 2003 Jul; 18(4):301-8. PubMed ID: 12858129
[TBL] [Abstract][Full Text] [Related]
12. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?
Tenenbaum A; Fisman EZ; Motro M; Adler Y
Adv Cardiol; 2008; 45():127-153. PubMed ID: 18230960
[TBL] [Abstract][Full Text] [Related]
13. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
[TBL] [Abstract][Full Text] [Related]
14. [Diabetic dyslipidaemia and the atherosclerosis].
Márk L; Dani G
Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
[TBL] [Abstract][Full Text] [Related]
15. Diabetic dyslipidaemia: insights for optimizing patient management.
Vergès B
Curr Med Res Opin; 2005; 21 Suppl 1():S29-40. PubMed ID: 15811197
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Boden WE
Curr Opin Cardiol; 2003 Jul; 18(4):278-85. PubMed ID: 12858126
[TBL] [Abstract][Full Text] [Related]
17. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
18. Hypertriglyceridemia and residual dyslipidemia in statin-treated, patients with diabetes at the highest risk for cardiovascular disease and achieving very-low low-density lipoprotein-cholesterol levels.
Querton L; Buysschaert M; Hermans MP
J Clin Lipidol; 2012; 6(5):434-42. PubMed ID: 23009779
[TBL] [Abstract][Full Text] [Related]
19. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
Hausenloy DJ; Yellon DM
Heart; 2008 Jun; 94(6):706-14. PubMed ID: 18480348
[TBL] [Abstract][Full Text] [Related]
20. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
